Viking Therapeutics, Inc. (VKTX)
Automate Your Wheel Strategy on VKTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VKTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VKTX
- Rev/Share 0.0
- Book/Share 7.5571
- PB 3.5966
- Debt/Equity 0.0012
- CurrentRatio 44.2458
- ROIC -0.2032
- MktCap 3052585800.0
- FreeCF/Share -1.1956
- PFCF -22.7827
- PE -23.7534
- Debt/Assets 0.0012
- DivYield 0
- ROE -0.1441
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VKTX | Cantor Fitzgerald | -- | Overweight | -- | $104 | April 29, 2025 |
| Initiation | VKTX | Goldman | -- | Neutral | -- | $30 | April 8, 2025 |
| Initiation | VKTX | Scotiabank | -- | Sector Outperform | -- | $102 | Feb. 13, 2025 |
| Initiation | VKTX | Citigroup | -- | Neutral | -- | $38 | Feb. 7, 2025 |
| Initiation | VKTX | JP Morgan | -- | Overweight | -- | $80 | Sept. 11, 2024 |
News
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Read More
Viking Therapeutics: Weight-Loss Story Remains Intact
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Positive
Viking Therapeutics remains a promising weight-loss drug biotech due to the enrollment of new promising trials. The weight-loss sector's momentum has faded some, but Eli Lilly and Novo Nordisk have still generated substantial value for shareholders. Viking Therapeutics has upcoming catalysts, including late-July Phase 2 oral data and Phase 3 injectable trial enrollment, potentially driving significant upside in the stock.
Read More
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Viking targets massive, validated markets with GLP-1/GIP and THR-β agonists, offering injectable and oral alternatives with promising Phase 2/3 results. Positioned as a second-line, tolerable, patient-friendly treatment in an established space with significant addressable market size. Compared to some other binary bets in big pharma, Viking offers leaner operations, lower complexity, faster trial execution, and less execution risk.
Read More
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Published: May 06, 2025 by: The Motley Fool
Sentiment: Positive
One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in April.
Read More
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Published: May 02, 2025 by: The Motley Fool
Sentiment: Positive
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Read More
1 Beaten-Down Stock to Buy and Hold for 10 Years
Published: May 01, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics (VKTX 3.44%) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors.
Read More
Why Viking Therapeutics Stock Popped Again Today
Published: April 29, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Viking Therapeutics (VKTX 11.41%) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.
Read More
Why Viking Therapeutics Stock Popped Today
Published: April 28, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics (VKTX 0.40%) stock inched 2.3% higher through 10:20 a.m. ET Monday, and for a most curious reason.
Read More
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Is Viking Therapeutics Stock (VKTX) Nearing A Bottom?
Published: April 21, 2025 by: See It Market
Sentiment: Neutral
With earnings scheduled for the 23rd, Viking Therapeutic's (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates. The spotlight will be on three clinical candidates: VK2735 (targeting obesity), VK2809 (for non-alcoholic steatohepatitis, or NASH), and VK0214 (for X-linked adrenoleukodystrophy, or X-ALD).
Read More
Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)
Published: April 17, 2025 by: Seeking Alpha
Sentiment: Positive
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market strategy, as the management announces its first supply and manufacturing partnership.
Read More
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
Read More
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Read More
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Published: April 14, 2025 by: The Motley Fool
Sentiment: Positive
Bad news for Pfizer (PFE 1.07%) turned into good news for Eli Lilly (LLY 2.42%), Novo Nordisk (NVO 2.23%), and Viking Therapeutics (VKTX 8.48%) Monday morning, each of which is rising on Pfizer's latest product announcement.
Read More
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study
Published: March 26, 2025 by: Investors Business Daily
Sentiment: Positive
Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study. The post Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study appeared first on Investor's Business Daily.
Read More
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
Published: March 19, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics (VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.
Read More
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
Read More
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Published: March 12, 2025 by: The Motley Fool
Sentiment: Negative
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics (VKTX 10.22%) and Roche Holdings (RHHBY 3.62%), up 11.3% and 4%, respectively, through 10:05 a.m.
Read More
Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.
Published: March 12, 2025 by: Market Watch
Sentiment: Positive
Viking has found a manufacturing partner, removing a key overhang on the stock.
Read More
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
Read More
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade)
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral
The sell-off in unprofitable stocks has hit tech and growth sectors hard, with investors seeking safety in healthcare and consumer staples. Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity. VKTX's $900M cash reserves and sufficient liquidity mitigate near-term funding risks, crucial amid current market uncertainties and lack of partnerships.
Read More
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.
Published: March 11, 2025 by: Investors Business Daily
Sentiment: Negative
Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735. The post Viking Therapeutics Just Inked A $150 Million Manufacturing Deal.
Read More
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Published: February 28, 2025 by: The Motley Fool
Sentiment: Positive
Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.
Read More
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Published: February 26, 2025 by: MarketBeat
Sentiment: Neutral
The GLP-1 industry is currently an oligopoly ruled by two pharmaceutical giants, Novo Nordisk A/S NYSE: NVO, maker of semaglutide under the Ozempic and Wegovy name brands, and Eli Lilly & Co. NYSE: LLY, maker of tirzepatide and dual GLP-1/GIP agonist treatment sold under Mounjaro and Zepbound name brands. As compounding facilities cease making compounded versions of their drugs, which are no longer on the FDA drug shortage list, the medical sector oligopoly will likely regain many more users to seal their dominance.
Read More
Is Viking Therapeutics a Buy Right Now?
Published: February 26, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics (VKTX -3.01%) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss. The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.
Read More
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not
Read More
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
Read More
Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Published: February 24, 2025 by: The Motley Fool
Sentiment: Positive
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%.
Read More
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Read More
About Viking Therapeutics, Inc. (VKTX)
- IPO Date 2015-04-28
- Website https://www.vikingtherapeutics.com
- Industry Biotechnology
- CEO Dr. Brian Lian Ph.D.
- Employees 45